Laporan Laba Rugi (TTM)
Laporan Laba Rugi Pharma-Bio Serv, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2020 10-31 |
2021 01-31 |
2021 04-30 |
2021 07-31 |
2021 10-31 |
2022 01-31 |
2022 04-30 |
2022 07-31 |
2022 10-31 |
2023 01-31 |
2023 04-30 |
2023 07-31 |
2023 10-31 |
2024 01-31 |
2024 04-30 |
2024 07-31 |
2024 10-31 |
2025 01-31 |
2025 04-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22 | 21 | 21 | 20 | 20 | 21 | 21 | 20 | 19 | 19 | 18 | 18 | 17 | 15 | 13 | 11 | 10 | 10 | 10 |
| Change (%) | -0.58 | -2.83 | -6.19 | 2.93 | 2.64 | -0.36 | -1.04 | -4.71 | -4.02 | -2.17 | -1.08 | -5.77 | -10.95 | -14.46 | -16.69 | -11.74 | 0.96 | 0.41 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 15 | 15 | 15 | 14 | 15 | 15 | 15 | 15 | 15 | 14 | 13 | 13 | 12 | 11 | 9 | 8 | 7 | 7 | 7 |
| Change (%) | 0.98 | -0.19 | -4.60 | 3.01 | 4.08 | 0.00 | -1.77 | -3.77 | -5.35 | -3.89 | -3.29 | -6.74 | -9.69 | -13.55 | -13.38 | -13.18 | -2.02 | -2.35 | |
| % of Revenue | 69.08 | 70.17 | 72.07 | 73.30 | 73.35 | 74.38 | 74.65 | 74.10 | 74.84 | 73.80 | 72.51 | 70.89 | 70.16 | 71.15 | 71.90 | 74.76 | 73.54 | 71.37 | 69.41 |
| Gross Operating Profit | 7 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 3 | 3 | 3 | 3 |
| Change (%) | -4.06 | -9.04 | -10.30 | 2.71 | -1.32 | -1.42 | 1.10 | -7.40 | -0.09 | 2.68 | 4.75 | -3.41 | -13.91 | -16.69 | -25.17 | -7.47 | 9.24 | 7.29 | |
| % of Revenue | 30.92 | 29.83 | 27.93 | 26.70 | 26.65 | 25.62 | 25.35 | 25.90 | 25.16 | 26.20 | 27.49 | 29.11 | 29.84 | 28.85 | 28.10 | 25.24 | 26.46 | 28.63 | 30.59 |
| SG&A | 4 | 4 | 4 | 4 | 9 | 9 | 9 | 9 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Change (%) | -1.20 | -2.79 | -3.35 | 123.49 | -1.16 | -1.00 | 0.54 | -59.11 | 0.61 | 0.83 | 3.90 | 1.07 | 1.58 | -0.86 | -1.82 | -2.58 | -2.99 | -0.40 | |
| % of Revenue | 20.59 | 20.47 | 20.47 | 21.10 | 45.80 | 44.11 | 43.83 | 44.52 | 19.11 | 20.03 | 20.65 | 21.69 | 23.26 | 26.53 | 30.75 | 36.24 | 40.00 | 38.44 | 38.13 |
| R&D | |||||||||||||||||||
| Change (%) | |||||||||||||||||||
| % of Revenue | |||||||||||||||||||
| OpEx | 19 | 19 | 19 | 18 | 24 | 24 | 24 | 24 | 18 | 17 | 17 | 17 | 16 | 15 | 13 | 12 | 11 | 11 | 10 |
| Change (%) | 0.48 | -0.77 | -4.33 | 29.93 | 2.06 | -0.37 | -0.91 | -24.54 | -4.13 | -2.88 | -1.70 | -4.91 | -6.88 | -10.10 | -9.92 | -9.72 | -2.36 | -1.67 | |
| % of Revenue | 89.68 | 90.63 | 92.55 | 94.39 | 119.16 | 118.49 | 118.48 | 118.63 | 93.94 | 93.84 | 93.15 | 92.57 | 93.42 | 97.68 | 102.65 | 111.00 | 113.54 | 109.81 | 107.54 |
| Operating Income | 2 | 2 | 2 | 1 | -4 | -4 | -4 | -4 | 1 | 1 | 1 | 1 | 1 | 0 | -0 | -1 | -1 | -1 | -1 |
| Change (%) | -9.78 | -22.69 | -29.39 | -451.58 | -0.95 | -0.42 | -0.24 | -130.98 | -2.32 | 8.66 | 7.29 | -16.50 | -68.63 | -197.86 | 245.57 | 8.64 | -26.88 | -22.84 | |
| % of Revenue | 10.32 | 9.37 | 7.45 | 5.61 | -19.16 | -18.49 | -18.48 | -18.63 | 6.06 | 6.16 | 6.85 | 7.43 | 6.58 | 2.32 | -2.65 | -11.00 | -13.54 | -9.81 | -7.54 |
| Interest Expense | -0 | ||||||||||||||||||
| Change (%) | |||||||||||||||||||
| % of Revenue | -0.33 | ||||||||||||||||||
| Net Income | 2 | 2 | 1 | 3 | -2 | -2 | -2 | -4 | 1 | 1 | 1 | 2 | 1 | 1 | -0 | -1 | -1 | -0 | -0 |
| Change (%) | -12.62 | -24.96 | 117.72 | -171.36 | -1.78 | 0.01 | 96.82 | -124.92 | 12.04 | 14.60 | 18.43 | -14.41 | -53.21 | -100.89 | 15,351.64 | -7.52 | -35.91 | -62.04 | |
| % of Revenue | 9.51 | 8.36 | 6.45 | 14.98 | -10.39 | -9.94 | -9.98 | -19.84 | 5.19 | 6.06 | 7.10 | 8.50 | 7.72 | 4.05 | -0.04 | -7.80 | -8.18 | -5.19 | -1.96 |
Source: Capital IQ
